Outcome of 5-Azacitidine and Decitabine Treatment in Elderly Patients with Myelodysplastic Syndrome

被引：0
|
作者：
Nam, Seung-Hyun [1 ]
Lim, Taekyu [1 ]
Kim, Bong-Seog [1 ]
机构：
[1] VHS Med Ctr, Seoul, South Korea
来源：
BLOOD | 2012年 / 120卷 / 21期
关键词：
D O I：
10.1182/blood.V120.21.4959.4959
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4959
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Poor Outcome of Patients with Myelodysplastic Syndrome (MDS) After Azacitidine Treatment Failure
    Lin, Karen
    Reljic, Tea
    Kumar, Ambuj
    Lancet, Jeffrey E.
    List, Alan F.
    Komrokji, Rami S.
    BLOOD, 2010, 116 (21) : 1199 - 1200
  • [32] Pre-transplant 5-azacitidine (Vidaza®) may improve outcome of allogeneic hematopoietic cell transplantation (HCT) in patients with myelodysplastic syndrome (MDS).
    Field, Teresa
    Perkins, Janelle
    Alsina, Melissa
    Ayala, Ernesto
    Fernandez, Hugo F.
    Janssen, William
    Kharfan-Dabaja, Mohamed
    Lancet, Jeffery
    Perez, Lia
    Sullivan, Daniel
    List, Alan
    Anasetti, Claudio
    BLOOD, 2006, 108 (11) : 1047A - 1047A
  • [33] EXPERIENCE WITH 5-AZACITIDINE IN PATIENTS DIAGNOSED BY MYELODYSPLASTIC SYNDROMES OF INTERMEDIATE 2/HIGH RISK
    Llorente Dunia, De Miguel
    Lopez Nuria, Golbano
    Morfa Miguel, Diaz
    Juanis Jaime, Arbeteta
    Sanz Dolores, Morales
    Ramo Alejandro, Vazquez
    Maqueda Cristina, Fernandez
    Garcia Helga, Guillen
    Perez Dolores, Subira
    Martin Sonia, Herrero
    Albiz Blanca, Pinedo
    HAEMATOLOGICA, 2016, 101 : 341 - 341
  • [34] The Effect of 5-Azacitidine Treatment on the Biologic Characteristics of Bone Marrow Mesenchymal Stem Cells in Patients with Myelodysplastic Syndromes
    Liapis, Ioannis
    Batsali, Aristea
    Mitrakos, Anastasios
    Kouvidi, Elisavet
    Galanopoulos, Athanasios
    Pontikoglou, Charalampos
    Kanavakis, Emmanouil
    Papadaki, Helen A.
    BLOOD, 2017, 130
  • [35] Outcome of Patients With Myelodysplastic Syndrome After Failure of Decitabine Therapy
    Jabbour, Elias
    Garcia-Manero, Guillermo
    Batty, Nicolas
    Shan, Jenny
    O'Brien, Susan
    Cortes, Jorge
    Ravandi, Farhad
    Issa, Jean-Pierre
    Kantarjian, Hagop
    CANCER, 2010, 116 (16) : 3830 - 3834
  • [36] Impact of neutropenia on the outcome of decitabine (DAC) treatment in patients (pts) with myelodysplastic syndrome (MDS).
    Pemmaraju, N.
    Kantarjian, H.
    Faderl, S.
    Garcia-Manero, G.
    Kadia, T. M.
    Borthakur, G.
    Cortes, J. E.
    Kashani, F. Ravandi
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [37] Infectious complications in patients with myelodysplastic syndromes: A review of the literature with emphasis on patients treated with 5-azacitidine
    Radsak, Markus
    Platzbecker, Uwe
    Schmidt, Cornelia S.
    Hofmann, Wolf-Karsten
    Nolte, Florian
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2017, 99 (02) : 112 - 118
  • [38] INFECTIOUS COMPLICATIONS IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES/ACUTE MYELOID LEUKEMIA TREATED WITH 5-AZACITIDINE
    Ramos, S.
    Santos, M.
    Tenreiro, R.
    Pereira, M.
    Cortesao, E.
    Rito, L.
    Ribeiro, M. L.
    HAEMATOLOGICA, 2015, 100 : 474 - 475
  • [39] ASSOCIATION OF 5-AZACITIDINE AND RUXOLITINIB AS TREATMENT FOR PATIENTS WITH MYELOFIBROSIS IN PROGRESSION
    Garcia Fortes, M.
    Dominguez Rivas, Y.
    Fernadez Fernandez, A.
    Rosell Mas, A.
    Revelles Penas, M.
    Garcia Delgado, R.
    HAEMATOLOGICA, 2017, 102 : 286 - 287
  • [40] The Tolerability of Combination Therapy with Thalidomide and 5-Azacitidine in Patients with Advanced Myelodysplastic Syndromes (MDS).
    Kenealy, Melita K.
    Seymour, John F.
    Linda, Cowan
    Milner, Alvin
    Giri, Pratyush
    Ho, Shir-Jing
    Benson, Warwick
    Nicol, Andrew
    Campbell, Philip
    Prosser, Ian
    Underhill, Craig
    Cunningham, Ilona
    Mills, Anthony K.
    Szer, Jeffrey
    Presgrave, Peter
    Filshie, Robin
    BLOOD, 2009, 114 (22) : 695 - 695
12345